V
Vanina Alzogaray
Researcher at Fundación Instituto Leloir
Publications - 13
Citations - 925
Vanina Alzogaray is an academic researcher from Fundación Instituto Leloir. The author has contributed to research in topics: Antibody & Antigen. The author has an hindex of 8, co-authored 11 publications receiving 815 citations.
Papers
More filters
Journal ArticleDOI
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.
Janusz Wesolowski,Vanina Alzogaray,Jan Reyelt,Mandy Unger,Karla Juarez,Karla Juarez,Mariela Urrutia,Ana Cauerhff,Welbeck Danquah,Björn Rissiek,Felix Scheuplein,Nicole Schwarz,Sahil Adriouch,Olivier Boyer,Michel Seman,Alexei Licea,David V. Serreze,Fernando Alberto Goldbaum,Friedrich Haag,Friedrich Koch-Nolte +19 more
TL;DR: The results of several recent proof-of-principle studies are reviewed that open the exciting perspective of using sdAbs for modulating immune functions and for targeting toxins and microbes.
Journal ArticleDOI
Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo
Friedrich Koch-Nolte,Jan Reyelt,Britta Schößow,Nicole Schwarz,Felix Scheuplein,Stefan Rothenburg,Friedrich Haag,Vanina Alzogaray,Ana Cauerhff,Fernando Alberto Goldbaum +9 more
TL;DR: A proof of principle that opens up a new avenue for targeting leukocyte ecto‐enzymes in vivo and that can serve as a model also for developing new antidotes against ADP‐ribosylating toxins is formed.
Journal ArticleDOI
Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT.
Mandy Unger,Anna Marei Eichhoff,Lucas Schumacher,Moritz Strysio,Stephan Menzel,Carsten Schwan,Vanina Alzogaray,Vanesa Zylberman,Michel Seman,Johanna M. Brandner,Holger Rohde,Kai Zhu,Friedrich Haag,Hans-Willi Mittrücker,Fernando Alberto Goldbaum,Klaus Aktories,Friedrich Koch-Nolte +16 more
TL;DR: The generation of functional nanobodies against the enzymatic CDTa and the heptameric receptor binding subunit CDTb hold promise as new tools for research, diagnosis and therapy of C. difficile associated disease.
Journal Article
Development of a hyperimmune equine serum therapy for COVID-19 in Argentina
Vanesa Zylberman,Santiago Sanguineti,Andrea Pontoriero,Sandra V Higa,Maria Laura Cerutti,Maria Laura Cerutti,Susana M Morrone Seijo,Romina Paola Pardo,Luciana Muñoz,María E Acuña Intrieri,María E Acuña Intrieri,Vanina Alzogaray,Martín Avaro,Estefanía Benedetti,Paula Mercedes Berguer,Laura Bocanera,Lucas Bukata,Marina S Bustelo,Ana M. Campos,Mariana Colonna,Elisa Correa,Lucía Cragnaz,María Elena Dattero,María Dellafiore,Sabrina Foscaldi,Joaquín V González,Luciano L Guerra,Sebastián Klinke,María S. Labanda,Constanza Lauché,Juan Carlos Lozano López,Anabela M Martínez,Lisandro H. Otero,Elías H Peyric,Pablo F Ponziani,Romina Ramondino,Jimena Rinaldi,Santiago Rodríguez,Javier E Russo,Mara Russo,Soledad L Saavedra,Mauricio Seigelchifer,Santiago Sosa,Claudio Vilariño,Patricia López Biscayart,Esteban Corley,Linus Spatz,Elsa Baumeister,Fernando A. Goldbaum,Fernando A. Goldbaum +49 more
TL;DR: In this paper, a new therapeutic product obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein was presented, which showed around 50 times more potency in in vitro seroneutralization assays than the average of convalescent plasma.
Journal ArticleDOI
Single-domain llama antibodies as specific intracellular inhibitors of SpvB, the actin ADP-ribosylating toxin of Salmonella typhimurium
Vanina Alzogaray,Welbeck Danquah,Andrés Aguirre,Mariela Urrutia,Paula Mercedes Berguer,Eleonora García Véscovi,Friedrich Haag,Friedrich Koch-Nolte,Fernando Alberto Goldbaum +8 more
TL;DR: The development of a single‐domain antibody from an immunized llama that blocks the capacity of SpvB to ADP‐ribosylate actin at a molar ratio of 1:1 is reported, paving the way for developing new antidotes against intracellular toxins.